Literature DB >> 34804885

Effect of breast-conserving surgery plus radiotherapy versus mastectomy on breast cancer-specific survival for early-stage contralateral breast cancer.

Chao Qian1, Yan Liang2, Min Yang3, Sheng-Nan Bao2, Jian-Ling Bai3, Yong-Mei Yin2, Hao Yu3.   

Abstract

BACKGROUND: Breast-conserving surgery followed by radiotherapy is recommended in most women with early-stage unilateral breast cancer. However, its role in contralateral breast cancer (CBC) patients remains unclear. This retrospective study aimed to evaluate the breast cancer-specific survival (BCSS) outcomes after breast-conserving surgery plus radiotherapy compared with mastectomy in women with early-stage (T1-2N0-1M0) CBC.
METHODS: Data were extracted from the Surveillance, Epidemiology, and End Results database. BCSS was analyzed using the log-rank method, competing risks regression model, and propensity score matching method.
RESULTS: A total of 9,336 early-stage CBC patients were included. After multivariable adjustment, no significant difference in BCSS was found between early-stage CBC patients undergoing breast-conserving surgery plus radiotherapy and those undergoing mastectomy [hazard ratio (HR) 1.11, 95% confidence interval (CI): 0.90-1.37, P=0.329]. BCSS was similar in both treatment groups and in the subgroups stratified by age at first primary breast cancer or CBC diagnosis (≤50, 51-60, and >60 years), time interval between cancers (<0.25, 0.25-4, 5-9, and ≤10 years), stage of first primary breast cancer, T classification of CBC, histology and hormone receptors status of both cancers (all P>0.05). Among patients with N1 disease at CBC diagnosis, breast-conserving surgery plus radiotherapy was associated with a boundary significantly improved BCSS (HR 1.45, 95% CI: 1.00-2.12, P=0.050). Among patients who underwent breast-conserving surgery for first primary cancer, bilateral mastectomy for contralateral cancer did not improve BCSS compared with breast-conserving surgery plus radiotherapy (P>0.05). There was no significant difference in BCSS between breast-conserving surgery plus radiotherapy and mastectomy plus radiotherapy (P>0.05). Stable results were obtained after propensity score matching.
CONCLUSIONS: Breast-conserving surgery plus radiotherapy did not significantly influence BCSS outcomes of patients with early-stage CBC. Bilateral mastectomy and mastectomy plus radiotherapy did not confer a survival advantage over breast-conserving surgery plus radiotherapy in these patients. Future prospective studies are necessary to expand on these results. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Breast-conserving surgery (BCS); contralateral breast cancer (CBS); mastectomy; survival

Year:  2021        PMID: 34804885      PMCID: PMC8575704          DOI: 10.21037/gs-21-413

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  46 in total

1.  Cancer treatment and survivorship statistics, 2019.

Authors:  Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-06-11       Impact factor: 508.702

2.  Bilateral breast-conserving therapy for bilateral breast cancer: results and consideration of radiation technique.

Authors:  Chikako Yamauchi; Michihide Mitsumori; Yasushi Nagata; Masaki Kokubo; Takashi Inamoto; Keiichi Mise; Hiroshi Kodama; Masahiro Hiraoka
Journal:  Breast Cancer       Date:  2005       Impact factor: 4.239

3.  Breast-conserving therapy is safe both within BRCA1/2 mutation carriers and noncarriers with breast cancer in the Chinese population.

Authors:  Xin Huang; Xiu-Yu Cai; Jia-Qi Liu; Wen-Wen Hao; Yi-Dong Zhou; Xiang Wang; Ying Xu; Chang Chen; Yan Lin; Chang-Jun Wang; Yu Song; Qiang Sun
Journal:  Gland Surg       Date:  2020-06

4.  Association of Breast Cancer Surgery With Quality of Life and Psychosocial Well-being in Young Breast Cancer Survivors.

Authors:  Shoshana M Rosenberg; Laura S Dominici; Shari Gelber; Philip D Poorvu; Kathryn J Ruddy; Julia S Wong; Rulla M Tamimi; Lidia Schapira; Steven Come; Jeffrey M Peppercorn; Virginia F Borges; Ann H Partridge
Journal:  JAMA Surg       Date:  2020-11-01       Impact factor: 14.766

5.  Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group.

Authors:  R Arriagada; M G Lê; F Rochard; G Contesso
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

6.  Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status.

Authors:  E Shelley Hwang; Daphne Y Lichtensztajn; Scarlett Lin Gomez; Barbara Fowble; Christina A Clarke
Journal:  Cancer       Date:  2013-01-28       Impact factor: 6.860

7.  Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.

Authors:  D Steinmann; M Bremer; D Rades; B Skawran; C Siebrands; J H Karstens; T Dörk
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

8.  Surgical management for early-stage bilateral breast cancer patients in China.

Authors:  Jia-jian Chen; Nai-si Huang; Jing-yan Xue; Chen-lian Quan; Yu-long Tan; Guang-yu Liu; Zhi-min Shao; Jiong Wu
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

9.  Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

Authors:  P McGale; C Taylor; C Correa; D Cutter; F Duane; M Ewertz; R Gray; G Mannu; R Peto; T Whelan; Y Wang; Z Wang; S Darby
Journal:  Lancet       Date:  2014-03-19       Impact factor: 79.321

10.  Comparison of long-term results between radiotherapy after breast-conserving surgery and postmastectomy radiotherapy in stage T1-2N1M0 breast cancer.

Authors:  Xiao-Wen Lan; Ge Wen; Zhen He; Jiang-Hua Huang; Xue-Bin Zou; Xiao Lin; Yu-Ting Tan; Xiao-Bo Huang
Journal:  Cancer Manag Res       Date:  2019-07-11       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.